Apollomics Change in Accounts Receivable 2021-2024 | APLM

Apollomics change in accounts receivable from 2021 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.

Apollomics Change in Accounts Receivable 2021-2024 | APLM

Apollomics change in accounts receivable from 2021 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.5B
Amgen (AMGN)$165.9B
Gilead Sciences (GILD)$140.8B
Vertex Pharmaceuticals (VRTX)$121.3B
Bristol Myers Squibb (BMY)$99.6B
CSL (CSLLY)$86.2B
GSK (GSK)$78.3B
Regeneron Pharmaceuticals (REGN)$61B
Alnylam Pharmaceuticals (ALNY)$42.8B
Argenex SE (ARGX)$36.2B
BioNTech SE (BNTX)$27.5B
Royalty Pharma (RPRX)$20.6B
Insmed (INSM)$19.6B
Biogen (BIIB)$19.4B
Illumina (ILMN)$17B
Genmab (GMAB)$15.2B
Genmab (GNMSF)$14.9B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.2B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.5B
QIAGEN (QGEN)$11.4B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.3B
Exact Sciences (EXAS)$9.2B
Bio-Techne Corp (TECH)$9.2B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.7B